Frazier Life Sciences Management, L.P. Pliant Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 1,120,803 shares of PLRX stock, worth $3.45 Million. This represents 0.89% of its overall portfolio holdings.
Number of Shares
1,120,803Holding current value
$3.45 Million% of portfolio
0.89%Shares
1 transactions
Others Institutions Holding PLRX
# of Institutions
175Shares Held
64.8MCall Options Held
228KPut Options Held
772K-
Deep Track Capital, LP Greenwich, CT5.97MShares$18.4 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$15.3 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.63MShares$14.3 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$9.94 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.2MShares$9.85 Million1.61% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $150M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...